Skip to main content

Clinical Trials Search at Vanderbilt-Ingram Cancer Center



An Open-Label, Dose-Escalation / Dose-Expansion Safety Study of INCB059872 in Subjects With Advanced Malignancies

Multiple Cancer Types

This is an open-label, dose-escalation / dose-expansion study of INCB059872 in subjects with advanced malignancies. The study will be conducted in 4 parts. Part 1 (mono therapy dose escalation) will determine the recommended dose(s) of INCB059872 for dose expansion, based on maximum tolerated dose and / or a tolerated pharmacologically active dose. Part 2 (dose expansion) will further determine the safety, tolerability, efficacy, PK, and PD of the selected monotherapy dose(s) in AML / MDS, SCLC, myelofibrosis, Ewing sarcoma, and poorly differentiated neuroendocrine tumors. Part 3 will determine the recommended dose(s) of INCB059872 in combination with azacitadine and all-trans retinoic acid in AML and in combination with nivolumab in SCLC. Part 4 will further determine the safety, tolerability, efficacy, PK, and PD of the selected combination dose(s) in Part 3.
Hematologic, Leukemia, Lung, Miscellaneous, Small Cell
I/II
Savona, Michael
NCT02712905
VICCHEMP1615

A Study of Ipatasertib in Combination With Paclitaxel as a Treatment for Participants With PIK3CA / AKT1 / PTEN-Altered, Locally Advanced or Metastatic, Triple-Negative Breast Cancer or Hormone Receptor-Positive, HER2-Negative Breast Cancer

Breast

This study will evaluate the efficacy of ipatasertib + paclitaxel versus placebo + paclitaxel in participants with histologically confirmed, locally advanced or metastatic triple-negative breast cancer (TNBC) and in participants with locally advanced or metastatic hormone receptor positive (HR+) / human epidermal growth factor receptor 2 negative (HER2?) breast adenocarcinoma who are not suitable for endocrine therapy.
Breast
III
Abramson, Vandana
NCT03337724
VICCBRE1767

A Study Exploring the Safety and Efficacy of INCAGN01949 in Combination With Immune Therapies in Advanced or Metastatic Malignancies

Multiple Cancer Types

The purpose of this study is to determine the safety, tolerability, and efficacy of INCAGN01949 when given in combination with immune therapies in participants with advanced or metastatic malignancies.
Bladder, Breast, Cervical, Colon, Dermatologic, Endocrine, Esophageal, Gastric/Gastroesophageal, Gastrointestinal, Head/Neck, Hepatoblastoma (Pediatrics), Kidney (Renal Cell), Liver, Lung, Melanoma, Miscellaneous, Non Small Cell, Ovarian, Phase I, Rectal, Small Cell, Urologic
I/II
Chism, David
NCT03241173
VICCUROP1777

Olaparib with or without Cediranib in Treating Patients with Metastatic Castration-Resistant Prostate Cancer

Prostate

This randomized phase II trial studies how well olaparib with or without cediranib works in treating patients with castration-resistant prostate cancer that has spread to other places in the body. Olaparib and cediranib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
Prostate
II
Chism, David
NCT02893917
VICCURO1782

A Trial of AP32788 in Non-Small Cell Lung Cancer

Multiple Cancer Types

The purpose of this phase 1 / 2 study is to evaluate the safety, pharmacokinetics, and anti-tumor activity of oral AP32788 in patients with non-small cell lung cancer (NSCLC). The trial will be conducted in two parts: a dose escalation phase, followed by an expansion phase. The goal of the dose escalation phase is to determine the safety profile of orally administered AP32788, including the maximum tolerated dose (MTD), dose limiting toxicities (DLTs), recommended phased 2 dose (RP2D) and pharmacokinetic profile. Once the RP2D is established, the expansion phase will assess the preliminary anti-tumor activity of AP32788 in 4 histologically and molecularly defined NSCLC cohorts. Approximately 105 patients will be enrolled.
Lung, Non Small Cell
I/II
Horn, Leora
NCT02716116
VICCTHO1614

A Study of Olaratumab (LY3012207) in Participants With Advanced Soft Tissue Sarcoma

Sarcoma

The main purpose of this study is to evaluate the safety and efficacy of two anti-cancer drugs (gemcitabine and docetaxel) with and without the study drug known as olaratumab in participants with advanced soft tissue sarcoma (STS) or STS that has spread to another part(s) of the body.
Sarcoma
I/II
Keedy, Vicki
NCT02659020
VICCSAR15131

A Study of Ruxolitinib vs Best Available Therapy (BAT) in Patients With Steroid-refractory Chronic Graft vs. Host Disease (GvHD) After Bone Marrow Transplantation (REACH3)

The purpose of this study is to assess the efficacy of ruxolitinib against best available therapy in participants with steroid-refractory chronic graft-versus-host disease (SR cGvHD).
Not Available
III
Jagasia, Madan
NCT03112603
VICCBMT1760

An Investigational Immuno-therapy Study of Nivolumab Compared to Temozolomide, Each Given With Radiation Therapy, for Newly-diagnosed Patients With Glioblastoma (GBM, a Malignant Brain Cancer)

Neuro-Oncology

The purpose of this study is to evaluate patients with glioblastoma that is MGMT-unmethylated (the MGMT gene is not altered by a chemical change). Patients will receive Nivolumab every two weeks in addition to radiation therapy, and then every four weeks. They will be compared to patients receiving standard therapy with temozolomide in addition to radiation therapy.
Neuro-Oncology
III
Clark, Stephen
NCT02617589
VICCNEU1644

A Phase 2 Multicenter Study Evaluating Subjects With Relapsed / Refractory Mantle Cell Lymphoma

Lymphoma

Study KTE-C19-102 is a phase 2, multicenter, open-label study evaluating the efficacy of KTE-C19 in subjects with Relapsed / Refractory MCL
Lymphoma
II
Oluwole, Olalekan
NCT02601313
VICCBMT15116

FLASH [Fluorescent Light Activated Synthetic Hypericin] Clinical Study: Topical SGX301 (Synthetic Hypericin) for the Treatment of Cutaneous T-Cell Lymphoma (Mycosis Fungoides)

To evaluate the use of SGX301, a topical photosensitizing agent, to treat patients with patch / plaque phase cutaneous T-cell lymphoma (mycosis fungoides).
Not Available
III
Zwerner, Jeffrey
NCT02448381
VICCDERM1572

To learn more about any of our clinical
trials, call 1-800-811-8480 or complete
the online Self-Referral Form here: